top of page
grain.png

TECHNOLOGY

WORLD'S FIRST BRAIN AREA SPECIFIC BIOMARKER

Treating mental health disorders using data originating deep in the brain. 

model coefficients
arrow.png
arrow.png

Simultaneous fMRI and EEG acquisitions

Advanced Statistical Models

Brain area-specific EEG-fMRI-Pattern (EFP) Biomarker

GMH's core technology is the first PTSD treatment based on a digital biomarker of brain activity associated with mental health disorders. The proprietary EEG-fMRI-Pattern (EFP) digital biomarker was developed by applying advanced statistical models to register amygdala fMRI data to EEG. This has never been done before. 

The company's flagship product, Prism for PTSD, uses the amygdala-based biomarker because research has shown that PTSD is associated with hyperactivity of the amygdala, the center of our fight-flight response.

Prism for PTSD gathers years of neuroscience research and places it into the hands of mental healthcare providers. Combining an innovative software with an affordable FDA-approved EEG headset for neurofeedback makes it is easy to integrate Prism into any clinic caring for PTSD patients. Designed for rapid deployment, the team is trained in the morning and patients can be treated the same afternoon.  

CROSSING THE BRIDGE FROM IDEA TO BIOMARKER

The National Institute of Mental Health (NIMH), Division of Translational Research convened a virtual workshop where researchers and FDA officials reviewed the state of the science for neurofeedback (NF) intervention for mental disorders. The program highlighted Prof. Talma Hendler, MD, PhD presenting how she and her team developed the innovative amygdala-based EFP biomarker in the research lab, and insights on the journey to FDA clearance and the use of Prism for PTSD for patient care in clinics today.

Watch Prof. Hendler's presentation "Crossing the Bridge from Idea to Biomarkerhere.

Anchor 1
Crossing the Bridge
bottom of page